Abion

Abion P/B

The P/B (Price-to-Book Ratio) of Abion (203400.KQ) as of Nov 1, 2026 is 4.69. In the previous year, P/B (Price-to-Book Ratio) was 11.40 — a change of -58.85% (lower).

P/B

4.69

YoY

-58.85%

Last updated:

P/B (Price-to-Book Ratio) of Abion is 2025 4.69 . P/B (Price-to-Book Ratio) of Abion was 2024 11.40 . It decreases by -58.85% lower compared to the previous year.

The Abion P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
130.45 KRW
Jan 1, 2019
-29.12 KRW
Jan 1, 2020
-16.01 KRW
Jan 1, 2021
9.99 KRW
Jan 1, 2022
21.24 KRW
Jan 1, 2023
32.14 KRW
Jan 1, 2024
11.40 KRW
Jan 1, 2025
4.69 KRW
The Abion P/B history
YEARP/BYoY
4.69-58.85%
11.40-64.52%
32.14+51.31%
21.24+112.59%
9.99-162.42%
-16.01-45.03%
-29.12-122.32%
130.45+18.23%
110.34+84.52%
59.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Abion Stock analysis

What does Abion do? ABION, Inc. generates revenue through its Product segment, which sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment offers histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services to clients in the biopharmaceutical industry. The Research segment focuses on developing drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics, with potential future commercialization. The company's business model relies on these four segments to serve biopharmaceutical companies seeking innovative diagnostic tools and therapeutic solutions. The Product segment targets biopharmaceutical firms requiring laboratory supplies for research and diagnostics. The CRO Service segment caters to clients needing specialized analytical services for drug development. The Research segment develops proprietary therapeutics that may be licensed or sold to partners in the pharmaceutical sector. ABION's revenue streams are derived from direct sales of reagents and services, as well as potential future licensing agreements from its research pipeline. ABION's business model integrates product sales, CRO services, and R&D activities to address multiple needs within the biopharmaceutical value chain. The company's diagnostic reagents and research reagents are sold directly to laboratories and research institutions. The CRO services are contracted by biopharmaceutical companies for specialized testing during drug development. The Research segment's focus on protein, nucleic acid, and antibody therapeutics positions ABION to develop novel treatments for incurable diseases, with commercialization opportunities through partnerships or direct sales. Abion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abion stock

P/B (Price-to-Book Ratio) of Abion is 4.69 in 2025.

P/B (Price-to-Book Ratio) of Abion changed from 11.40 to 4.69, representing a -58.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Abion since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Abion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Abion

All Key Metrics — Abion